Overview

Adaptimmune is a clinical stage biotechnology company with clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. Adaptimmune partners with industry leaders in all areas of its business.

We are passionate about our SPEAR T-cell therapies, and we are always looking for the right technology partnerships to deliver for people living with cancer.

The Company has alliances with a range of partners listed below.

We have several existing manufacturing partnerships, providing vector supply into 2019. The agreement with Cell and Gene Therapy (CGT) Catapult, will enable us to have our own dedicated GMP (Good Manufacturing Practices) vector manufacturing space in the UK.

View Partner

We signed a major collaboration and license agreement in June 2014 for up to five programs including the first program, NY-ESO, which we recently transitioned to GSK.

View Partner

Adaptimmune has a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center signed in 2016 designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.

View Partner

At the heart of the collaboration, is the Dynabeads CD3/CD28 Cell Therapy System (CTS™), which play a central role in the manufacture of the engineered autologous SPEAR T-cells.

View Partner